

CITATIONS

1. Costa LG, McDonald BE, Murphy SD, Omenn GS, Richter RJ, Motulsky AG, Furlong CE. 1990. Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats. *Toxicol Appl Pharmacol* 103(1):66-76.
2. Furlong CE, Richter RJ, Chapline C, Crabb JW. Purification of rabbit and human serum paraoxonase. 1991. *Biochemistry* 30(42):10133-40.
3. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Mycoskie CJ, Furlong CE. 1991. Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. *Biochemistry* 22;30(42):10141-9.
4. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. *Nat Genet* 3(1):73-6.
5. Li WF, Costa LG, Furlong CE. 1993. Serum paraoxonase status: a major factor in determining resistance to organophosphates. *J Toxicol Environ Health* 40:337±346.
6. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. 1996. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. *Nat Genet* 14(3):334-6.
7. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusic AJ. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. *Nature* 394(6690):284-7
8. Li WF, Costa LG, Richter RJ, Hagen T, Shih DM, Tward A, Lusic AJ, Furlong CE. 2000. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. *Pharmacogenetics* 10(9):767-79.
9. CHAMACOS Study. 2023. UC Berkeley School of Public Health. Available: <https://cerch.berkeley.edu/research-programs/chamacos-study> [accessed March 17, 2023]
10. Richter RJ, Furlong CE. 1999. Determination of paraoxonase (PON1) status requires more than genotyping. *Pharmacogenetics* 9(6):745-53.
11. Brophy, VH, Jarvik, GP, Richter, RJ, Rozek, LS, Schellenberg, GD, Furlong, CE. 2000. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. *Pharmacogenetics* 10(5), 453-460.
12. Jarvik, G., Jampsa, R, Richter, RJ, Carlson, CS, Rieder, MJ, Nickerson, DA, Furlong, CE. 2003. Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status. *Pharmacogenetics* 13(5), 291-295.
13. Chen, J, Kumar, M, Chan, W, Berkowitz, G, Wetmur, JG. 2003. Increased influence of genetic variation on PON1 activity in neonates. *Environmental health perspectives* 111(11), 1403-1409.
14. Furlong, CE, Holland, N, Richter, RJ, Bradman, A, Ho, A, Eskenazi, B. 2006. PON1 status of farmworker mothers and children as a predictor of organophosphate sensitivity. *Pharmacogenetics and genomics* 16(3), 183-190.
15. Holland, N, Furlong, C, Bastaki, M, Richter, R, Bradman, A, Huen, K, Eskenazi, B. 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. *Environmental health perspectives* 114(7), 985-991.
16. Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusic AJ, Jack RM, Costa LG, Furlong CE. 2003. Expression of human paraoxonase (PON1) during development. *Pharmacogenetics* 13(6):357-64.
17. Roy TS, Seidler FJ, Slotkin TA. 2004. Morphologic effects of subtoxic neonatal chlorpyrifos exposure in developing rat brain: regionally selective alterations in neurons and glia. *Brain Res Dev Brain Res* 148:197-206.

18. Roy TS, Sharma V, Seidler FJ, Slotkin TA. 2005. Quantitative morphological assessment reveals neuronal and glial deficits in hippocampus after a brief subtoxic exposure to chlorpyrifos in neonatal rats. *Brain Res Dev Brain Res* 155:71–80.
19. Rauh, VA, Perera, FP, Horton, MK, Whyatt, RM, Bansal, R, Hao, X, Peterson, BS. 2012. Brain anomalies in children exposed prenatally to a common organophosphate pesticide. *Proc Natl Acad Sci USA* 109(20), 7871-7876.
20. Cole TB, Walter BJ, Shih DM, Tward AD, Lulis AJ, Timchalk C, Richter RJ, Costa LG, Furlong CE. 2005. Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism. *Pharmacogenet Genomics* 15(8):589-98.
21. Berkowitz, GS, Wetmur, JG, Birman-Deych, E, Obel, J, Lapinski, RH, Godbold, JH, Wolff, MS. 2004. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. *Environmental health perspectives* 112(3), 388-391.
22. Wolff, MS, Engel, S, Berkowitz, G, Teitelbaum, S, Siskind, J, Barr, DB, Wetmur, J. 2007. Prenatal pesticide and PCB exposures and birth outcomes. *Pediatric research* 61(2), 243-250.
23. Eskenazi, B, Huen, K, Marks, A, Harley, KG, Bradman, A, Barr, DB, Holland, N. 2010. PON1 and neurodevelopment in children from the CHAMACOS study exposed to organophosphate pesticides in utero. *Environmental health perspectives* 118(12), 1775-1781.
24. Engel, SM, Wetmur, J, Chen, J, Zhu, C, Barr, DB, Canfield, RL, Wolff, MS. 2011. Prenatal exposure to organophosphates, paraoxonase 1, and cognitive development in childhood. *Environmental Health Perspectives* 119(8), 1182-1188.
25. Harley, KG, Huen, K, Aguilar Schall, R, Holland, NT, Bradman, A, Barr, DB, Eskenazi, B. 2011. Association of organophosphate pesticide exposure and paraoxonase with birth outcome in Mexican-American women. *PloS one* 6(8), e23923.
26. Rauch, SA, Braun, J. M, Barr, DB, Calafat, AM, Khoury, J, Montesano, AM, Lanphear, B. P. 2012. Associations of prenatal exposure to organophosphate pesticide metabolites with gestational age and birth weight. *Environmental Health Perspectives* 120(7), 1055-1060.
27. Eskenazi, B, Kogut, K, Huen, K, Harley, KG, Bouchard, M, Bradman, A, Holland, N. 2014. Organophosphate pesticide exposure, PON1, and neurodevelopment in school-age children from the CHAMACOS study. *Environmental research* 134, 149-157.
28. Stevens RC, Suzuki SM, Cole TB, Park SS, Richter RJ, Furlong CE. 2008. Engineered recombinant human paraoxonase 1 (rHuPON1) purified from *Escherichia coli* protects against organophosphate poisoning. *Proc Natl Acad Sci USA* 105(35):12780-4.
29. Richter RJ, Jarvik GP, Furlong CE. 2008. Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. *Circ Cardiovasc Genet* 1(2):147-52.
30. Hofmann JN, Keifer MC, Furlong CE, De Roos AJ, Farin FM, Fenske RA, van Belle G, Checkoway H. 2009. Serum cholinesterase inhibition in relation to paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesticide handlers. *Environ Health Perspect* 117(9):1402-8.
31. Cole TB, Li WF, Co AL, Hay AM, MacDonald JW, Bammler TK, Farin FM, Costa LG, Furlong CE. 2014. Repeated gestational exposure of mice to chlorpyrifos oxon is associated with paraoxonase 1 (PON1) modulated effects in maternal and fetal tissues. *Toxicol Sci* 141(2):409-22.
32. Hertz-Picciotto I, Sass JB, Engel S, Bennett DH, Bradman A, Eskenazi B, Lanphear B, Whyatt R. 2018. Organophosphate exposures during pregnancy and child neurodevelopment: Recommendations for essential policy reforms. *PLoS Med* 24;15(10):e1002671.
33. U.S. Environmental Protection Agency. 2021. Tolerance Revocations: Chlorpyrifos. Final rule. *Fed Reg Doc* No 2021-18091. Volume 86, No 165, (48315-48336).